• Elias Kyriakou, Ignatios Ikonomidis, Dimitrios Stylos, Stefanos Bonovas, Ioannis Papadakis, Georgios K Nikolopoulos, Styliani Kokoris, Dimitrios Kalantzis, Christine Economopoulou, Petros Kopterides, John Lekakis, and Argirios E Tsantes.
• Laboratory of Haematology & Blood Bank Unit, "Attiko" University Hospital, School of Medicine, University of Athens, Athens, Greece.
• Clin. Appl. Thromb. Hemost. 2015 Jul 1;21(5):434-45.

BackgroundOur aim was to identify laboratory assays in order to assess the anticoagulant effects of dabigatran etexilate (DE).MethodsTwenty patients with nonvalvular atrial fibrillation treated on DE (110 mg per os twice daily) and 20 on acenocoumarol were studied. Conventional coagulation tests, endogenous thrombin potential (ETP), thromboelastometry (ROTEM), epinephrine-induced light transmission aggregometry (LTA), and Hemoclot Thrombin Inhibitors (HTI) were performed in all patients.ResultsIn ROTEM analysis, the lysis index at 60 minutes was significantly lower in patients receiving DE (P = .011). In LTA, patients on DE showed decreased aggregation compared to those on acenocoumarol, marginally insignificant (P = .068). Regarding ETP, acenocoumarol affected thrombin generation more than dabigatran (area under the curve [AUC], P < .001), while statistically significant associations were detected between dabigatran levels, as determined by the HTI assay, and almost all parameters of ETP assay (AUC, P < .001).ConclusionThe role of ETP in estimating anticoagulant activity of dabigatran possibly requires further research.© The Author(s) 2014.

17 keywords...

hide…